芬兰基因库与英国生物银行中凝血因子V Leiden与凝血酶原G20210A单杂合及双杂合携带者的血栓形成风险
利用英国生物银行与芬兰基因库共937939人的多维数据,评估凝血因子V Leiden(FVL)与凝血酶原G20210A(PTGM)双杂合(DH)携带者的临床影响。662名(0.07%)为DH携带者,校正年龄、性别和祖先后,DH个体静脉血栓栓塞(VTE)风险显著升高(OR=5.24;95%CI 4.01-6.84;P=4.8×10⁻³⁴),近似于FVL纯合子所赋予的风险;DH基因型与任何动脉血栓表型风险显著升高无关。
要点
- DH携带者占0.07%,VTE风险OR=5.24(95%CI 4.01-6.84),近似FVL纯合子。
- 英国生物银行亚组校正BMI、血型、炎症标志物后,DH的OR=4.53(95%CI 3.42-5.90)。
- DH基因型与卒中、心肌梗死、外周动脉疾病等动脉血栓风险显著升高无关。
核心结论
- DH基因型的发生频率可能与FVL纯合子相当,并可能赋予相似的VTE风险升高。
- DH基因型与任何动脉血栓表型风险显著升高无关。
研究设计与样本
- 利用英国生物银行(UKB)与芬兰基因库(FinnGen)生物样本库的多维数据,纳入937939名个体评估DH携带状态的临床影响。
- 二次分析仅限UKB参与者(N=445144),校正BMI、血型及炎症标志物等常见VTE危险因素。
主要发现
- 662名参与者(0.07%)为DH携带者。
- 校正年龄、性别和祖先后,DH个体VTE风险显著高于野生型个体(OR=5.24;95%CI 4.01-6.84;P=4.8×10⁻³⁴),近似于FVL纯合子所赋予的风险。
- UKB二次分析中,校正BMI、血型及炎症标志物后,DH基因型的效应量估计基本不变(OR=4.53;95%CI 3.42-5.90;P<1×10⁻¹⁶)。
- DH基因型与卒中、心肌梗死、外周动脉疾病等任何动脉血栓表型风险显著升高无关。
关键数值与推荐
- DH携带者662人(0.07%),VTE风险OR=5.24(95%CI 4.01-6.84;P=4.8×10⁻³⁴),近似FVL纯合子。
- UKB亚组(N=445144)校正后DH的VTE风险OR=4.53(95%CI 3.42-5.90;P<1×10⁻¹⁶)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The factor V Leiden (FVL; rs6025) and prothrombin G20210A (PTGM; rs1799963) polymorphisms are 2 of the most well-studied genetic risk factors for venous thromboembolism (VTE). However, double heterozygosity (DH) for FVL and PTGM remains poorly understood, with previous studies showing marked disagreement regarding thrombosis risk conferred by the DH genotype. Using multidimensional data from the UK Biobank (UKB) and FinnGen biorepositories, we evaluated the clinical impact of DH carrier status across 937 939 individuals. We found that 662 participants (0.07%) were DH carriers. After adjustment for age, sex, and ancestry, DH individuals experienced a markedly elevated risk of VTE compared with wild-type individuals (odds ratio [OR] = 5.24; 95% confidence interval [CI], 4.01-6.84; P = 4.8 × 10-34), which approximated the risk conferred by FVL homozygosity. A secondary analysis restricted to UKB participants (N = 445 144) found that effect size estimates for the DH genotype remained largely unchanged (OR = 4.53; 95% CI, 3.42-5.90; P < 1 × 10-16) after adjustment for commonly cited VTE risk factors, such as body mass index, blood type, and markers of inflammation. In contrast, the DH genotype was not associated with a significantly higher risk of any arterial thrombosis phenotype, including stroke, myocardial infarction, and peripheral artery disease. In summary, we leveraged population-scale genomic data sets to conduct, to our knowledge, the largest study to date on the DH genotype and were able to establish far more precise effect size estimates than previously possible. Our findings indicate that the DH genotype may occur as frequently as FVL homozygosity and may confer a similarly increased risk of VTE.
引用
- Ryu J, Rämö JT, Jurgens SJ, et al. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood. 2024. PMID: 38498041. doi:10.1182/blood.2023023326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。